Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Company Profile
- CEO
- Kevin Tang
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 137
- Beta
- 0.45
- Country
- US
Financials
Net Income
$-14.00MEBITDA
$-13.88MFree Cash Flow
$-15.10MEPS (diluted)
$-0.37Shares Outstanding (diluted)
37.92M+41.0%Operating Expenses
$4.08MCash & Debt
$95.03MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2020 | $0.00 | $-126.35M | $-3.85 |
| 2019 | $0.00 | $-111.83M | $-4.05 |
| 2018 | $0.00 | $-88.96M | $-3.64 |
| 2017 | $0.00 | $-32.74M | $-1.28 |
| 2016 | $0.00 | $-3.08M | $-0.11 |
| 2015 | $0.00 | $-158.0K | $-0.01 |
Valuation
ODThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+9.09%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·21d ago·Positive
Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder Transcript Definium Therapeutics, Inc. (DFTX) Discusses Topline Results from Panorama Phase 3 Study of DT120 ODT in Generalized Anxiety Disorder Transcript
View source ↗ - Newsgurufocus.com·22d ago·Neutral
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026 Definium Therapeutics, Inc. (âDefiniumâ or the âCompanyâ), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics i
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Definium Therapeutics: 'Strong Buy' On Positive DT120 ODT Data, Two Indications, And September 2026 Catalyst Definium Therapeutics remains a 'Strong Buy' following positive phase 3 VOYAGE data for DT120 ODT in generalized anxiety disorder [GAD]. The company's DT120 ODT achieved a statistically significant -5.4 placebo-adjusted reduction in HAM-A score at 12 weeks in GAD, highlighting best-in-class potential. Upcoming catalysts include phase 3 PANORAMA GAD data in September 2026 and ASCEND MDD to
View source ↗
Earnings
Typical surprise -1.9% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 27$-0.58 vs $-0.33miss
- Fri, May 14$-0.90 vs $-0.85miss
- Tue, Feb 23$-0.87 vs $-0.77miss
- Wed, Oct 28$-0.93 vs $-1.19beat
- Thu, Jul 30$-1.09 vs $-1.07miss
- Tue, Apr 28$-0.99 vs $-1.02beat
Estimates and results for ODT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ODT officers and directors.
- Bought
- $18.3m
- Sold
- $20.7m
13 trades
22 trades
- Ecor1 Capital, Llcsold
- Ecor1 Capital, Llcsold
- Ecor1 Capital, Llcsold
- Ecor1 Capital, Llcsold
- Ecor1 Capital, Llcbought
- Boxer Capital, Llcsold
- Boxer Capital, Llcsold
- Davis Aaron I.sold
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ODT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.